Immunovant
320 West 37th Street
New York
NY
10018
United States
Tel: 9145222605
23 articles about Immunovant
-
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/7/2022
Immunovant, Inc. today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022.
-
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
12/30/2021
Immunovant, Inc. announced that the Company achieved alignment with the FDA Division of Neurology 1 (“FDA”) to move forward in myasthenia gravis (“MG”). Immunovant plans to start its Phase 3 study for batoclimab in MG in the first half of calendar year 2022. T
-
In addition to the beginnings of the Jazz PTSD study, Revive announced its Phase III study of Bucillamine in patients with mild to moderate COVID-19 will continue.